In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merz Pharmaceuticals GmbH

Division of Merz GmbH & Co. KGaA
www.merz.de

Latest From Merz Pharmaceuticals GmbH

Another Botox Competitor: Revance Prepares Longer-Lasting RT002 For BLA Submission

A claim that RT002's duration of efficacy surpasses the leading neurotoxin – Allergan's blockbuster Botox – will be put to the test when Revance seeks US FDA approval to treat frown lines in the first half of this year. The company's Botox biosimilar with Mylan also could move forward in 2019.

Aesthetics Business Strategies

With Jeuveau Approval, Evolus Will Focus On The Beauty Business To Gain Market Share

Evolus believes its focus on the beauty business will be a differentiator for its neurotoxin Jeuveau. The company will publish head-to-head results against Botox alongside the Spring 2019 launch and does not expect a new trade secrets complaint from Botox maker Allergan to delay its product.

Approvals Launches

Medical Aesthetics: A Untapped Pharma Market With Incoming Competition

Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.

Business Strategies Growth

Medical Aesthetics: A Untapped Pharma Market With Incoming Competition

Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.

Commercial Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Neurology, Nervous System
  • Otolaryngology
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Merz GmbH & Co. KGaA
  • Senior Management
  • Martin Zugel, PhD, CEO
    Karsten Schlemm, Head, Int'l Mktg. & Sales
    Alexander Gebauer, MD, Head, R&D
  • Contact Info
  • Merz Pharmaceuticals GmbH
    Phone: (49) 69 15 03 0
    Alfred-Wegener-Straße 2
    Frankfurt, D-60438
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register